西酞普兰对女性慢性精神分裂症患者临床症状和生活质量的影响

Influence of Citalopram on Clinical Symptoms and Quality of Life of Female Patients with Chronic Schizophrenia

目的:探讨西酞普兰对女性慢性精神分裂症患者的疗效。方法:将52例女性慢性精神分裂症患者分为研究组和对照组,在原药物治疗基础上分别加用小剂量西酞普兰和安慰剂治疗12周,并用阳性和阴性症状量表(PANSS)、生活质量综合评定问卷(GQOLI-74)、临床疗效总评量表(CGI-SI)进行评定。结果:治疗前两组各量表评分差异均无显著性(P>0.05),治疗后研究组PANSS阴性因子分、一般精神病理量表分、总分及反应缺乏因子、抑郁因子分较治疗前明显下降(20.0±4.2/27.6±4.6,30.1±2.6/37.1±6.3,62.7±7.3/76.6±10.7,9.4±1.9/12.2±1.7,7.7±1.0/10.2±1.3,t=4.21～7.72,P<0.01),研究组的生活质量综合评定问卷总分及各维度评分均高于对照组(如总分40.7±7.0/33.1±3.6,t=4.64,P<0.01)。结论:西酞普兰可能改善女性慢性精神分裂症患者的临床症状和生活质量。

Objective： To explore the effect of Citalopram on clinical symptoms of chronic schizophrenia and life quality of female patients. Methods： 52 female patients with chronic schizophrenia were divided into the research group （ n = 30 ） and the control group （n = 22 ） . Originally used drugs were retained for both groups , Citalopram was added in research group, and placebo was added in control, both for 12 weeks, PANSS, GQOLI-74, CGI-SI were used to evaluate the effects. Results： At the end of treatment, the total scores of PANSS, factor scores of negative symptoms, general psychopathology, lack of reaction, and depression significantly decreased in the research group （ data P 〈 0. 01 ）, and significantly superior than the control group 120.0 ± 4. 2/27.6 ± 4. 6, 30. 1 ± 2.6/37. 1 ± 6. 3, 62.7 ±7.3/76.6±10.7, 9.4 ±1.9/12.2 ±1.7, 7.7 ±1.0/10.2 ±1.3, t=4.21-7.72） .After treatment, the research group had better life quality than the control group 1 40. 7 ± 7. 0/33.1 ± 3.6, t = 4. 64, P 〈 0. 01 ） . Conclusions： Citalopram may improve the clinical symptoms and the quality of life in female patients with chronic schizophrenia.